Ann: Kazia commences recruitment to GBM AGILE, page-2

Board of DirectorsMr Iain Ross Chairman,Non-Executive DirectorMr Bryce Carmine Non-Executive DirectorMr Steven Coffey Non-Executive DirectorDr James Garner Chief Executive Officer, Managing DirectorThree International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000ASX RELEASE7January 2021GBM AGILE PIVOTAL STUDY COMMENCES RECRUITMENT TO PAXALISIB ARMSydney,7January2021–Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the GBM AGILE pivotal study (NCT03970447) has commenced recruitment to the paxalisib arm. Key Points•GBM AGILE is an international adaptive, multi-drug study, designed to expedite the development of new therapies for glioblastoma•Kazia executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) in October 2020 to bring paxalisib into GBM AGILE•Lead investigators for the paxalisib arm are Professor Ingo Mellinghoff (Memorial SloanKettering Cancer Center) and Dr Eudocia Q Lee (Dana-Farber Cancer Institute)•Positive data from GBM AGILE is expected to support registration of paxalisib in the US and other key marketsKazia CEO, Dr James Garner, commented, “we are delighted to have recruitment underway, and this marks an important milestone for Kaziaas we begin the new year. The GBM AGILE study has secured the support of leading clinicians in the glioblastoma field, and has increasingly won the confidence of regulators and industry participants, sowe are excited to be a part of it. If the data from GBM AGILE is positive, we expect it to provide a basis for registration in glioblastoma, and it therefore represents an important step towards commercialisation of the drug.